Draxis BrachySeed deal with Cytogen

Draxis (TSE:DAX; DRAX) granted CYTO exclusive U.S. marketing rights to its BrachySeed implants for use in prostate cancer therapy in exchange for milestone payments and royalties. BrachySeed received ...